AXSM · Axsome Therapeutics, Inc.

Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $237.64 and $244.71.

Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $245.17 and $253.04.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.11 and $244.13.

Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.46 and $242.35.

Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan.

Represents an exercise of stock options which was held for over 8 years and exercised prior to the 10-year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest in full on the one-year anniversary of the date of grant.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest in full on the one-year anniversary of the date of grant.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest in full on the one-year anniversary of the date of grant.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

The RSUs vest in full on the one-year anniversary of the date of grant.

Represents the sale of underlying shares of previously exercised stock options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $221.82 and $225.21.

Represents the sale of underlying shares of previously exercised stock options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $229.56 and $232.14.

Represents the sale of underlying shares of previously exercised stock options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $231.50 and $235.23.

Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77.

Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $181.01 and $184.28.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.10 and $163.42.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.

Represents the sale of underlying shares of previously exercised stock options.

Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.33 and $162.26.

Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.

Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Such transaction was pursuant to a pre-approved 10b5-1 plan.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.